Puma Biotechnology, Inc. (PBYI) stock
PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.12−0.10 (-1.39%)
Close on Nov 19, 2026Market cap $367.54MP/E 13.7Yield –
Puma Biotechnology operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Puma Biotechnology's operating income for the twelve months ending Jun 30, 2026 was $30.44M, down 33.9% year over year. For fiscal 2025 it was $37.30M, up 20.5% from the year before. The highest annual figure on record is $37.30M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.30M | +20.5% |
| FY2024 | Dec 31, 2024 | $30.97M | -5.1% |
| FY2023 | Dec 31, 2023 | $32.64M | +37.6% |
| FY2022 | Dec 31, 2022 | $23.72M | +1738.8% |
| FY2021 | Dec 31, 2021 | $1.29M | – |
| FY2020 | Dec 31, 2020 | -$30.40M | – |
| FY2019 | Dec 31, 2019 | -$39.05M | – |
| FY2018 | Dec 31, 2018 | -$94.66M | – |
| FY2017 | Dec 31, 2017 | -$292.39M | – |
| FY2016 | Dec 31, 2016 | -$276.60M | – |
| FY2015 | Dec 31, 2015 | -$240.28M | – |
| FY2014 | Dec 31, 2014 | -$142.28M | – |
| FY2013 | Dec 31, 2013 | -$54.83M | – |
| FY2012 | Dec 31, 2012 | -$74.45M | – |
| FY2011 | Dec 31, 2011 | -$10.16M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.59M | +14.3% |
| Q1 FY2026 | Mar 31, 2026 | -$3.83M | -196.1% |
| Q4 FY2025 | Dec 31, 2025 | $17.11M | +28.0% |
| Q3 FY2025 | Sep 30, 2025 | $9.57M | -56.6% |
| Q2 FY2025 | Jun 30, 2025 | $6.64M | – |
| Q1 FY2025 | Mar 31, 2025 | $3.98M | – |
| Q4 FY2024 | Dec 31, 2024 | $13.37M | -9.7% |
| Q3 FY2024 | Sep 30, 2024 | $22.08M | +157.2% |
| Q2 FY2024 | Jun 30, 2024 | -$2.18M | -144.5% |
| Q1 FY2024 | Mar 31, 2024 | -$2.30M | -152.7% |
| Q4 FY2023 | Dec 31, 2023 | $14.80M | +47.7% |
| Q3 FY2023 | Sep 30, 2023 | $8.59M | +258.8% |
| Q2 FY2023 | Jun 30, 2023 | $4.89M | -59.4% |
| Q1 FY2023 | Mar 31, 2023 | $4.37M | – |
| Q4 FY2022 | Dec 31, 2022 | $10.02M | +46.6% |
| Q3 FY2022 | Sep 30, 2022 | $2.39M | – |
| Q2 FY2022 | Jun 30, 2022 | $12.06M | – |
| Q1 FY2022 | Mar 31, 2022 | -$747.00K | -103.7% |
| Q4 FY2021 | Dec 31, 2021 | $6.83M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.95M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.63M | -333.3% |
| Q1 FY2021 | Mar 31, 2021 | $20.15M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.15M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.13M | – |
| Q2 FY2020 | Jun 30, 2020 | $7.13M | – |
| Q1 FY2020 | Mar 31, 2020 | -$14.25M | -244.7% |
| Q4 FY2019 | Dec 31, 2019 | -$8.67M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.45M | – |
| Q2 FY2019 | Jun 30, 2019 | -$25.78M | – |
| Q1 FY2019 | Mar 31, 2019 | $9.85M | – |
| Q4 FY2018 | Dec 31, 2018 | -$18.54M | – |
| Q3 FY2018 | Sep 30, 2018 | -$11.28M | – |
| Q2 FY2018 | Jun 30, 2018 | -$41.44M | – |
| Q1 FY2018 | Mar 31, 2018 | -$23.39M | – |
| Q4 FY2017 | Dec 31, 2017 | -$63.57M | – |
| Q3 FY2017 | Sep 30, 2017 | -$77.44M | – |
| Q2 FY2017 | Jun 30, 2017 | -$78.18M | – |
| Q1 FY2017 | Mar 31, 2017 | -$73.20M | – |
| Q4 FY2016 | Dec 31, 2016 | -$72.87M | – |
| Q3 FY2016 | Sep 30, 2016 | -$66.00M | – |
See a number that looks wrong?